Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Related Experiment Video
Updated: Dec 3, 2025
Zachary J Walker1, Beau M Idler1, Lorraine N Davis1
1Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Purpose:
The prognosis of patients with multiple myeloma who are resistant to proteasome inhibitors, immunomodulatory drugs (IMiD), and daratumumab is extremely poor. Even B-cell maturation antigen-specific chimeric antigen receptor T-cell therapies provide only a temporary benefit before patients succumb to their disease. In this article, we interrogate the unique sensitivity of multiple myeloma cells to the alternative strategy of blocking protein translation with omacetaxine.
Experimental Design:
We determined protein translation levels (n = 17) and sensitivity to omacetaxine (n = 51) of primary multiple myeloma patient samples. Synergy was evaluated between omacetaxine and IMiDs in vitro, ex vivo, and in vivo. Underlying mechanism was investigated via proteomic analysis.
Results:
Almost universally, primary patient multiple myeloma cells exhibit >2.5-fold increased rates of protein translation compared with normal marrow cells. Ex vivo treatment with omacetaxine resulted in >50% reduction in viable multiple myeloma cells. In this cohort, high levels of translation serve as a biomarker for patient multiple myeloma cell sensitivity to omacetaxine. Unexpectedly, omacetaxine demonstrated synergy with IMiDs in multiple myeloma cell lines in vitro. In addition, in an IMiD-resistant relapsed patient sample, omacetaxine/IMiD combination treatment resensitized the multiple myeloma cells to the IMiD. Proteomic analysis found that the omacetaxine/IMiD combination treatment produced a double-hit on the IRF4/c-MYC pathway, which is critical to multiple myeloma survival.
Conclusions:
Overall, protein translation inhibitors represent a potential new drug class for myeloma treatment and provide a rationale for conducting clinical trials with omacetaxine alone and in combination with IMiDs for patients with relapsed/refractory multiple myeloma.
Insights
Omacetaxine effectively targets multiple myeloma cells by blocking protein translation, offering a new therapeutic strategy. This drug shows promise alone and in combination with immunomodulatory drugs (IMiDs) for relapsed/refractory disease.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma patients resistant to current therapies face a poor prognosis.
- Existing treatments like proteasome inhibitors, IMiDs, and daratumumab have limited efficacy in refractory cases.
- Chimeric antigen receptor T-cell therapies offer only transient benefits.
Purpose of the Study:
- To investigate omacetaxine, a protein translation inhibitor, as a therapeutic strategy for multiple myeloma.
- To determine the sensitivity of multiple myeloma cells to omacetaxine.
- To explore the synergistic effects of omacetaxine with immunomodulatory drugs (IMiDs).
Main Methods:
- Assessed protein translation levels in 17 primary multiple myeloma samples.
- Determined omacetaxine sensitivity in 51 primary multiple myeloma samples.
- Evaluated drug synergy in vitro, ex vivo, and in vivo using cell lines and patient samples.
- Conducted proteomic analysis to investigate underlying mechanisms.
Main Results:
- Multiple myeloma cells universally exhibit significantly higher protein translation rates than normal cells.
- Omacetaxine treatment reduced viable multiple myeloma cells by over 50% ex vivo.
- High translation rates identified as a biomarker for omacetaxine sensitivity.
- Omacetaxine demonstrated synergistic effects with IMiDs in vitro.
- Combination therapy resensitized IMiD-resistant cells and impacted the IRF4/c-MYC pathway.
Conclusions:
- Protein translation inhibitors represent a promising new drug class for multiple myeloma.
- Omacetaxine shows potential as a monotherapy or in combination with IMiDs.
- Clinical trials of omacetaxine are warranted for relapsed/refractory multiple myeloma patients.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers


